ANGLE plc (DWV) Stock Price & Analysis
DWV Stock Chart & Stats
- Day’s Range
- EUR 0.01 - EUR 0.01
- 52-Week Range
- EUR 0.01 - EUR 0.05
- Previous Close
- EUR 0.01
- Volume
- 0
- Average Volume (3M)
- 1,667
- Market Cap
- EUR 8.17M
- Enterprise Value
- EUR 15.77M
- Total Cash (Recent Filing)
- EUR 5.27M
- Total Debt (Recent Filing)
- EUR 3.67M
- Price to Earnings (P/E)
- ―
- Beta
- -6.98
- Next Earnings
- Apr 29, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strategic Partnerships Enabling Commercialization
A large medtech collaboration with Myriad Genetics creates durable commercial distribution capabilities and scales go-to-market reach for Parsortix. This structural partnership can accelerate adoption, provide commercialization expertise, and open payer and clinical channels beyond one-off research sales.
Validated Utility In Pharma Trials
Completion of major projects with Eisai and AstraZeneca provides strong clinical validation and product-market fit for drug development applications. Sustained pharma engagement supports recurring service and collaboration revenues and raises barriers to entry for competitors in trial workflows.
Conservative Leverage And Equity Buffer
Low debt-to-equity and a high equity ratio imply financial flexibility and lower insolvency risk, supporting continued R&D and commercialization efforts. This structural balance-sheet strength helps the company withstand near-term revenue volatility without excessive fixed financing costs.
Bears Say
Limited Cash Runway
A cash runway ending in Q1 2026 creates a structural financing risk that can force dilutive capital raises or constrain strategic investments. Management time and resources may be diverted to fundraising, slowing commercialization and accreditation execution over the next 2–6 months.
Weak Cash Generation
Negative operating cash conversion and declining free cash flow indicate the business currently cannot self-fund growth. This persistent cash shortfall increases reliance on external capital and limits sustainable investment in sales, clinical adoption, and lab accreditation initiatives.
Ongoing Profitability And Revenue Pressure
Negative revenue growth and margins show structural challenges converting commercialization progress into profitable operations. Continued losses and slim margins impair free cash flow generation, making it harder to scale operations and achieve durable profitability without operational restructuring or revenue expansion.
DWV FAQ
What was ANGLE plc’s price range in the past 12 months?
What is ANGLE plc’s market cap?
When is ANGLE plc’s upcoming earnings report date?
How were ANGLE plc’s earnings last quarter?
Is ANGLE plc overvalued?
Does ANGLE plc pay dividends?
What is ANGLE plc’s EPS estimate?
How many shares outstanding does ANGLE plc have?
What happened to ANGLE plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ANGLE plc?
What is the TipRanks Smart Score and how is it calculated?
Company Description
ANGLE plc
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1 system, a medical device engineered to isolate and collect whole circulating tumor cells (CTCs) from the blood of patients with metastatic breast cancer, preparing them for further user-validated analysis. The company also provides the Parsortix PR1 system for general CTC capture and collection from blood samples. Beyond its core systems, CelLBxHealth offers the Portrait+ CTC Staining kit, a laboratory solution designed for the precise identification, characterization, and quantification of both epithelial and mesenchymal circulating tumor cells, boasting strong analytical sensitivity and specificity. Another key product is the CellKeep Slide, which facilitates CTC harvesting. The company extends its expertise through various laboratory services, including advanced CTC enrichment and liquid biopsy analysis. Its assay portfolio comprises Portrait Flex, an immunofluorescence assay for detecting epithelial, mesenchymal, and epithelial-to-mesenchymal transition states, as well as assessing DNA damage response. Additionally, CelLBxHealth provides Portrait PD-L1 for CTC evaluation and develops customized CTC assays. Strategic collaborations underpin some of its development efforts; it has partnered with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. involves utilizing a pan-cancer next-generation sequencing (NGS) panel. Originally established in 1994 as ANGLE plc, the company rebranded to CelLBxHealth plc in October 2025 and operates from its base in Guildford, UK.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Peter Michael Collins
- Employees
- 114
- Website
- cellbxhealth.com
- Address
- Surrey Research Park, Guildford, SU, GU2 7AF, GB
ANGLE plc (DWV) Earnings & Revenues
DWV Earnings Call
Earnings Call SentimentNeutral
ANGLE's earnings call presented a balanced outlook with significant achievements in pharma collaborations and technology development, but also faced challenges from adverse market conditions affecting revenue and the need for additional funding.
View all DE:DWV earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 3 | 16 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 0 | 0 | 12 |
